Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard J Kelly

Showing results (31-40 of 41) with videos related to

Pageof 5
Sort By:
Advances in Therapy|July 28, 2025
Efficacy and Safety Maintained up to 3 Years in Adults with Paroxysmal Nocturnal Hemoglobinuria Receiving PegcetacoplanCarlos de Castro, Richard J Kelly, Morag Griffin, et al.
Blood|December 24, 2023
Treatment outcomes of complement protein C5 inhibition in 509 UK patients with paroxysmal nocturnal hemoglobinuriaRichard J Kelly, Matthew Holt, Jennifer Vidler, et al.
The New England Journal of Medicine|September 10, 2015
Eculizumab in Pregnant Patients with Paroxysmal Nocturnal HemoglobinuriaRichard J Kelly, Britta Höchsmann, Jeff Szer, et al.
Hematological Oncology|April 22, 2023
A phase 1b study of venetoclax and alvocidib in patients with relapsed/refractory acute myeloid leukemiaBrian A Jonas, Jing-Zhou Hou, Gail J Roboz, et al.
The Lancet. Haematology|July 5, 2022
COVID-19 vaccination antibody responses in patients with aplastic anaemia and paroxysmal nocturnal haemoglobinuriaAlexandra Pike, Claire McKinley, Briony Forrest, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 2017
Outcome of Azacitidine Therapy in Acute Myeloid Leukemia Is not Improved by Concurrent Vorinostat Therapy but Is Predicted by a Diagnostic Molecular SignatureCharles F Craddock, Aimee E Houlton, Lynn Swun Quek, et al.
Journal for Immunotherapy of Cancer|July 3, 2019
Plasmacytoid dendritic cells orchestrate innate and adaptive anti-tumor immunity induced by oncolytic coxsackievirus A21Louise M E Müller, Matthew Holmes, Joanne L Michael, et al.
American Journal of Hematology|June 17, 2024
Phase 3 randomized COMMODORE 2 trial: Crovalimab versus eculizumab in patients with paroxysmal nocturnal hemoglobinuria naive to complement inhibitionAlexander Röth, Guangsheng He, Hongyan Tong, et al.
Hemasphere|June 8, 2026
Iptacopan monotherapy resulted in increased hemoglobin level in patients with PNH and hemoglobin ≥10 g/dL after anti-C5 therapyAustin Kulasekararaj, Flore S de Fontbrune, Anna Gaya, et al.
The New England Journal of Medicine|March 13, 2024
Oral Iptacopan Monotherapy in Paroxysmal Nocturnal HemoglobinuriaRégis Peffault de Latour, Alexander Röth, Austin G Kulasekararaj, et al.
Pageof 5

Showing results (31-40 of 41) with videos related to

Sort By:
Pageof 5
Advances in Therapy|July 28, 2025
Efficacy and Safety Maintained up to 3 Years in Adults with Paroxysmal Nocturnal Hemoglobinuria Receiving PegcetacoplanCarlos de Castro, Richard J Kelly, Morag Griffin, et al.
Blood|December 24, 2023
Treatment outcomes of complement protein C5 inhibition in 509 UK patients with paroxysmal nocturnal hemoglobinuriaRichard J Kelly, Matthew Holt, Jennifer Vidler, et al.
The New England Journal of Medicine|September 10, 2015
Eculizumab in Pregnant Patients with Paroxysmal Nocturnal HemoglobinuriaRichard J Kelly, Britta Höchsmann, Jeff Szer, et al.
Hematological Oncology|April 22, 2023
A phase 1b study of venetoclax and alvocidib in patients with relapsed/refractory acute myeloid leukemiaBrian A Jonas, Jing-Zhou Hou, Gail J Roboz, et al.
The Lancet. Haematology|July 5, 2022
COVID-19 vaccination antibody responses in patients with aplastic anaemia and paroxysmal nocturnal haemoglobinuriaAlexandra Pike, Claire McKinley, Briony Forrest, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 2017
Outcome of Azacitidine Therapy in Acute Myeloid Leukemia Is not Improved by Concurrent Vorinostat Therapy but Is Predicted by a Diagnostic Molecular SignatureCharles F Craddock, Aimee E Houlton, Lynn Swun Quek, et al.
Journal for Immunotherapy of Cancer|July 3, 2019
Plasmacytoid dendritic cells orchestrate innate and adaptive anti-tumor immunity induced by oncolytic coxsackievirus A21Louise M E Müller, Matthew Holmes, Joanne L Michael, et al.
American Journal of Hematology|June 17, 2024
Phase 3 randomized COMMODORE 2 trial: Crovalimab versus eculizumab in patients with paroxysmal nocturnal hemoglobinuria naive to complement inhibitionAlexander Röth, Guangsheng He, Hongyan Tong, et al.
Hemasphere|June 8, 2026
Iptacopan monotherapy resulted in increased hemoglobin level in patients with PNH and hemoglobin ≥10 g/dL after anti-C5 therapyAustin Kulasekararaj, Flore S de Fontbrune, Anna Gaya, et al.
The New England Journal of Medicine|March 13, 2024
Oral Iptacopan Monotherapy in Paroxysmal Nocturnal HemoglobinuriaRégis Peffault de Latour, Alexander Röth, Austin G Kulasekararaj, et al.
Pageof 5